청소년과 사전 노출 예방요법(PrEP) 서비스 연결하기 (LYPS)
청소년을 노출 전 예방요법(PrEP) 서비스에 연결하기(LYPS): PrEP 순응도와 지속성을 최적화하기 위한 혁신적인 모바일 전달 및 모바일 헬스(mHealth) 중재
The LYPS intervention is a multi-level intervention that combines: a) structural-level delivery of PrEP and PrEP services by a community health professional (CHP) at a designated place in the community being offered by the SC where PrEP is not yet provided (e.g., participant's home, community partner location, or traveling mobile van), with b) an individual-level mobile application (app) to support PrEP adherence and persistence between CHP visits.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
LYPS is a two-arm randomized controlled trial (RCT) to assess the efficacy of the LYPS intervention. Up to 272 participants will be randomized in a 1:1 ratio to receive either the LYPS intervention or enhanced standard of care (eSOC) (136 participants per arm). The eSOC control condition will consist of usual clinic-based PrEP care and access to a limited number of LYPS app components. Participants will complete four research assessments, at Enrollment and Weeks 12, 24, and 36, that include computer-assisted self-interviews (CASIs) and blood collection. CASIs will collect information including, but not limited to, demographics, PrEP adherence and persistence, PrEP clinic visit attendance, PrEP knowledge and attitudes, PrEP self-efficacy, PrEP stigma, and psychosocial variables, questions that evaluate components of the LYPS intervention, tailored for intervention and eSOC conditions. Blood (dried blood spot [DBS] and plasma) will be collected to evaluate PrEP drug concentrations and stored for additional study-related testing.
All participants will receive daily oral PrEP, oral PrEP taken using a 2-1-1 dosing strategy, or injectable PrEP based on their preference and in consultation with their PrEP provider. There is no randomization involved for PrEP provision and participants are allowed to switch between oral and injectable PrEP or vice versa during the study. PrEP care visits (quarterly for those on oral PrEP and two monthly injections followed by an injection every two months for those on injectable PrEP) will include clinical labs such as HIV and STI testing and focused physical exams for signs and symptoms of HIV infection. Other relevant clinical data collected as part of the participant's PrEP clinical care will also be collected.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Nancy Liu
- 전화번호: 718-980-3937
- 이메일: NancyLiu@westat.com
연구 연락처 백업
- 이름: Erin Ricketts
- 전화번호: 240-453-2786
- 이메일: ErinRicketts@westat.com
연구 장소
-
-
California
-
San Francisco, California, 미국, 94102
- 모병
- San Francisco Department of Public Health
-
수석 연구원:
- Albert Liu
-
연락하다:
- Emily Schaeffer
- 전화번호: 628-217-7456
- 이메일: emily.schaeffer@sfdph.org
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- 모병
- Emory Atlanta Adolescent Consortium
-
수석 연구원:
- Andres Camacho-Gonzalez
-
연락하다:
- Kaylin Dance
- 전화번호: (404) 727-5642
- 이메일: kaylin.dance@emory.edu
-
-
Maryland
-
Baltimore, Maryland, 미국, 21287
- 모병
- Johns Hopkins University
-
연락하다:
- Jessica Coleman
- 전화번호: 301-385-4868
- 이메일: jcolem52@jh.edu
-
수석 연구원:
- Allison Agwu
-
-
Texas
-
Houston, Texas, 미국, 77030
- 모병
- Baylor College of Medicine
-
연락하다:
- Litty Koshy
- 전화번호: 832-822-1038
- 이메일: Litty.Koshy@bcm.edu
-
수석 연구원:
- Mary Paul
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age 13-24 years, inclusive;
- Reports anal or vaginal sex in the past year;
- Is not living with HIV;
- Weighs at least 35 kilograms (77 pounds);
- Willing to receive PrEP care from a provider at a participating SC either in the clinic or at one of the designated places in the community being offered by the SC SC;
- Has an Android-based smartphone or iPhone;
- Has fluency in English (able to read, speak, and understand English); and
- Willing to provide informed consent to participate in the study.
Exclusion Criteria:
- Has counter-indications for PrEP according to guidelines and approved local label;
- Has any clinically significant systemic disease (including but not limited to significant or uncontrolled liver disease, gastrointestinal disease, kidney disease, thyroid disease, osteoporosis, or bone disease) or diabetes;
- Any other medical, behavioral, or other conditions that, in the opinion of the SC project lead or designee, could interfere with adherence to study procedures or compromise interpretation of study results;
- Concurrent participation in ATN 166, ATN 170, or any other clinical trial providing HIV medications (PrEP, vaccine, etc.) or currently receiving any PrEP-adherence or persistence behavioral intervention; or
- Is currently incarcerated or pending incarceration.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: LYPS Intervention
PrEP and PrEP care will be delivered to youth in the communities where they live through a Community Health Professional (CHP) (e.g., a nurse or other qualified health care professional home, friend's home, community venue or clinic, mobile health clinic), supplemented by a mobile app to provide real-time intervention between CHP visits. |
The LYPS intervention combines the use of a CHP to deliver PrEP services at a designated place in the community being offered by the SC where PrEP is not yet provided (e.g., participant's home, community partner location, or traveling mobile van) with an android-based smartphone or iphone app to support PrEP use between CHP visits. |
|
활성 비교기: Enhanced Standard of Care (eSOC) Control Condition
Usual standard of care clinic-based PrEP, enhanced with access to a limited number of LYPS app components, including basic PrEP adherence information and study visit reminders. |
Clinic-based PrEP services per usual standard of care (e.g., HIV and STI testing, clinical assessments for signs and symptoms of HIV and PrEP safety) with access to a limited number of LYPS app components, including basic PrEP adherence information and study visit reminders. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
PrEP adherence at 6 months
기간: 6 months
|
Determine adherence outcomes as measured by blood will be tailored for oral PrEP modality (daily oral or 2-1-1) and target vs. non-target PrEP concentration thresholds (depending on regimen) will be examined. Adherence outcomes for participants on injectable PrEP will be determined by the timely (± 1 week for the second injection; ± 2 weeks for any subsequent injection) administration of injections. |
6 months
|
|
PrEP persistence at 6 months
기간: 6 months
|
Access persistence measures as based on 1) participant's self-report of currently taking PrEP (daily or 2-1-1) or having received last shot of injectable PrEP, and 2) has an active prescription for PrEP based on study records or drug level associated with use at 6 months. |
6 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
PrEP adherence at 9 months
기간: 9 months
|
Determine adherence outcomes as measured by blood will be tailored for oral PrEP modality (daily oral or 2-1-1) and target vs. non-target PrEP concentration thresholds (depending on regimen) will be examined. Adherence outcomes for participants on injectable PrEP will be determined by the timely (± 1 week for the second injection; ± 2 weeks for any subsequent injection) administration of injections. |
9 months
|
|
PrEP persistence at 9 months
기간: 9 months
|
Access persistence measures as based on 1) participant's self-report of currently taking PrEP (daily or 2-1-1) or having received last shot of injectable PrEP, and 2) has an active prescription for PrEP based on study records or drug level associated with use at 9 months. |
9 months
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Lisa Hightow-Weidman, MD, MPH, Florida State University
- 연구 의자: Kate Muessig, Florida State University
- 연구 의자: Keith Horvath, San Diego State University
- 연구 의자: Audrey Pettifor, UNC Chapel Hill
- 수석 연구원: Sybil Hosek, PhD, University of Illinois Chicago
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
기타 연구 ID 번호
- ATN165
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .